In what seems to have become a regular affair, the WHO has “has objected to the practice of Indian pharmaceutical companies misusing international non-proprietary names (INN) as trademark protected brand names.” If newspaper reports are to be believed…:
“In a recent letter to the Drugs Controller General of India (DCGI), the WHO has expressed concern over a trademark application filed by Cadila Pharmaceuticals for “platin”, a common name that is used for at least 18 medicines. Cadilla officials were not available for comment.”
The problem with this practice, according to WHO, is that it could mislead the customer in addition to being violative of international ethics. Raffaella Balocco Mattavelli, manager of the INN Programme, Quality Assurance and Safety Medicines, WHO, in his letter says:
“The registration of platin as trademark is particularly harmful, since it is identical to the INN stem (a portion of INN) ‘-platin’ used for antineoplastic agents, platinum derivates. Moreover, there are already 18 INNs ending with ‘-platin’. It is therefore important that such well-established INN stems should not be allowed to be used in or as trade-marks,”
It is also reported that this is not the first time and the WHO had brought this to the notice of DGCI earlier this year. Readers with more information on this are requested to share the same with us.